ReviewCancers2021
The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study.Cancer immunology, immunotherapy : CII · 2024Trial
- Microbiome-based diagnostic biomarkers in pancreatic ductal adenocarcinoma: Current evidence and translational challenges (Review).Oncology letters · 2026Review
- Gut microbiota reshaping the pancreatic cancer immune microenvironment: new avenues for immunotherapy.Molecular cancer · 2025Review
- Strategic modulation of the gastrointestinal microbiome to enhance pancreatic cancer immunotherapy.Drug discovery today · 2025Review
- Proteomics in pancreatic cancer.Biomarker research · 2025Review
- The association between exocrine pancreatic insufficiency and changes in gut microbiota: a narrative review.Medicine and pharmacy reports · 2025Review
- The human microbiota: a double-edged sword against the 'Sword of Damocles' in PDAC diagnosis and therapy.Frontiers in oncology · 2025Review
- Superparamagnetic iron oxide nanoparticle regulates microbiota-gut-inner ear axis for hearing protection.National science review · 2024Article
- Postbiotic butyrate: role and its effects for being a potential drug and biomarker to pancreatic cancer.Archives of microbiology · 2024Review
- Microbiome as a biomarker and therapeutic target in pancreatic cancer.BMC microbiology · 2024Review
- Unraveling the gut microbiome's contribution to pancreatic ductal adenocarcinoma: mechanistic insights and therapeutic perspectives.Frontiers in immunology · 2024Review
- Role of microbiota and microbiota-derived short-chain fatty acids in PDAC.Cancer medicine · 2023Review
- Intratumoral microbiota: implications for cancer onset, progression, and therapy.Frontiers in immunology · 2023Review
- The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC).Hepatobiliary surgery and nutrition · 2022Article
- Impact of microbiota-immunity axis in pancreatic cancer management.World journal of gastroenterology · 2022Review
- Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis.Cancer metastasis reviews · 2022Review
- Intratumor Microbiome in Neuroendocrine Neoplasms: A New Partner of Tumor Microenvironment? A Pilot Study.Cells · 2022Article
- Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.Frontiers in nutrition · 2022Review
- The Microbiome in Pancreatic Cancer-Implications for Diagnosis and Precision Bacteriophage Therapy for This Low Survival Disease.Frontiers in cellular and infection microbiology · 2022Review
- Microbiota in Pancreatic Diseases: A Review of the Literature.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers and is projected to be the second most common cause of cancer-related death by 2030, with an overall 5-year survival rate between 7% and 9%. Despite recent advances in surgical, chemotherapy, and radiotherapy techniques, the outcome for patients with PDAC remains poor. Poor prognosis is multifactorial, including the likelihood of sub-clinical metastatic disease at presentation, late-stage at presentation, absence of early and reliable diagnostic biomarkers, and complex biology surrounding the extensive desmoplastic PDAC tumour micro-environment. Microbiota refers to all the microorganisms found in an environment, whereas microbiome is the collection of microbiota and their genome within an environment. These organisms reside on body surfaces and within mucosal layers, but are most abundantly found within the gut. The commensal microbiome resides in symbiosis in healthy individuals and contributes to nutritive, metabolic and immune-modulation to maintain normal health. Dysbiosis is the perturbation of the microbiome that can lead to a diseased state, including inflammatory bowel conditions and aetiology of cancer, such as colorectal and PDAC. Microbes have been linked to approximately 10% to 20% of human cancers, and they can induce carcinogenesis by affecting a number of the cancer hallmarks, such as promoting inflammation, avoiding immune destruction, and microbial metabolites can deregulate host genome stability preceding cancer development. Significant advances have been made in cancer treatment since the advent of immunotherapy. The microbiome signature has been linked to response to immunotherapy and survival in many solid tumours. However, progress with immunotherapy in PDAC has been challenging. Therefore, this review will focus on the available published evidence of the microbiome association with PDAC and explore its potential as a target for therapeutic manipulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.